Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The subject matter disclosed herein relates to a method of treating glioblastoma (GBM) in a subject in need thereof, the method comprising determining one or more GBM subtypes in a GBM sample via a pathway-based classifier approach and administering to the subject a pharmaceutically effective amount of an agent capable of modifying the activity of the biological pathways associated with the one or more GMB subtypes.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The subject matter described herein relates to a method of regulating protein kinase activity by allosteric modifications such as prolyl hydroxylation.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The present disclosure provides, in one embodiment, a method of treating or preventing an ID2 protein-related disease in a patient at risk of developing or having such a disease by administering to the patient a composition in an amount and for a time sufficient to increase degradation of HIF? in a cell affected by the ID2 protein-related disease in the patent and/or to decrease half-life of HIF? in the cell affected by the ID2 protein-related disease in the patient, as compared to an untreated cell affected by the ID2 protein-related disease.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The present disclosure provides, in one embodiment, a method of treating or preventing an ID2 protein-related disease in a patient at risk of developing or having such a disease by administering to the patient a composition in an amount and for a time sufficient to increase degradation of HIF? in a cell affected by the ID2 protein-related disease in the patent and/or to decrease half-life of HIF? in the cell affected by the ID2 protein-related disease in the patient, as compared to an untreated cell affected by the ID2 protein-related disease.

Abstract: High-grade gliomas are the most common brain tumors in humans and are essentially incurable. The defining hallmark of these high-grade gliomas is the presence within the tumor mass of highly tumorigenic cellular subpopulations that fuel tumor aggressiveness. Identification of the molecular mechanisms remains elusive. Therefore, there is a need for diagnostic markers to accurately determine the type of glioma and appropriate treatment. Gene delivery vehicles are provided that comprise an oncogene, IRES-Cre-ER cassette and a gene encoding an oligonucleotide that inhibits p53 including shp53. Methods are also provided for determining a diagnosis and for treatment of non-aggressive and aggressive gliomas.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: High-grade gliomas are the most common brain tumors in humans and are essentially incurable. The defining hallmark of these high-grade gliomas is the presence within the tumor mass of highly tumorigenic cellular subpopulations that fuel tumor aggressiveness. Identification of the molecular mechanisms remains elusive. Therefore, there is a need for diagnostic markers to accurately determine the type of glioma and appropriate treatment. Gene delivery vehicles are provided that comprise an oncogene, IRES-Cre-ER cassette and a gene encoding an oligonucleotide that inhibits p53 including shp53. Methods are also provided for determining a diagnosis and for treatment of non-aggressive and aggressive gliomas.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The present invention provides a method for determining whether a subject has a pediatric neoplasm. The present invention further provides a method for assessing the efficacy of therapy to treat a pediatric neoplasm in a subject who has undergone or is undergoing treatment for a pediatric neoplasm. In addition, the present invention provides a method for assessing the prognosis of a subject who has a pediatric neoplasm. Finally, the present invention provides a method for treating a pediatric neoplasm in a subject in need of treatment thereof.

Abstract: The invention provides methods for the therapy of cancer that are directed towards preventing or inhibiting Id function. The present methods are based on contacting neoplastic or tumor cells with agents that can translocate an Id protein to the cytoplasm and/or sequester an Id protein in the cytoplasm, thereby preventing Id-mediated promotion of cell cycle activation and/or Id-mediated repression of cell differentiation. The invention also provides methods for screening agents that can be useful in the methods of treatment. The agents used in the methods can be, for example, proteins that possess: (1) at least one LIM domain, (2) at least one PDZ domain, or (3) at least one LIM domain and at least one PDZ domain. One particular agent that is used in the methods is the ENH (Enigma Homologue) protein, or peptides or peptidomimetics thereof.

Abstract: The present invention provides a method for determining whether a subject has a pediatric neoplasm. The present invention further provides a method for assessing the efficacy of therapy to treat a pediatric neoplasm in a subject who has undergone or is undergoing treatment for a pediatric neoplasm. In addition, the present invention provides a method for assessing the prognosis of a subject who has a pediatric neoplasm. Finally, the present invention provides a method for treating a pediatric neoplasm in a subject in need of treatment thereof.